Glenmark Pharmaceuticals Limited announced its quarterly results on August 14, 2020. Consolidated net revenue in Q1FY21 stood at Rs2,344.79cr, which increased by 0.94% yoy from Rs2,322.88cr in Q1FY20.
EBITDA stood at Rs478.07cr in Q1FY21 that increased by 39.82% yoy. For Q1FY20, it had posted EBITDA of Rs341.91cr. EBITDA margin as of Q1FY21 was at 20.39% that increased by 5.67% yoy against the same quarter, the previous year.
The consolidated net profit in Q1FY21 came in at Rs254.04cr that increased by 132.47% yoy, as compared to Q1FY20, when it had reported Rs109.28cr. The net profit margin in Q1FY21 came in at 10.83% that increased by 6.13% yoy. The net profit margin for Q1FY20 was at 4.7%.
The share closed at Rs475.4 with gains of 2.34% in today’s session on BSE.
|
Particulars |
Q1FY21 (Rs in cr) |
Q1FY20 (Rs in cr) |
% VAR |
|
Net Revenue |
2,344.79 |
2,322.88 |
0.94 |
|
Operating Profit |
478.07 |
341.91 |
39.82 |
|
Net Profit |
254.04 |
109.28 |
132.47 |
|
EBITDAM% |
20.39 |
14.72 |
5.67 |
|
PATM% |
10.83 |
4.7 |
6.13 |
Related Tags:
